Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 34 citing articles:

Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance
Tommaso Scolaro, Marta Manco, Mathieu Pecqueux, et al.
Nature Cancer (2024) Vol. 5, Iss. 8, pp. 1206-1226
Open Access | Times Cited: 16
Clinical applications of human organoids
Monique M.A. Verstegen, Robert P. Coppes, Anne Béghin, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 8
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling
Mingyao Huang, Xiaoqin Yu, Qing Wang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis
Francisco Cézar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Barbara Lins Silva, et al.
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access | Times Cited: 1
A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects
David Amilo, Chinedu Izuchukwu, Khadijeh Sadri, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 13
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials
Francisco Cézar Aquino de Moraes, Artur de Oliveira Macena Lôbo, Vitor Kendi Tsuchiya Sano, et al.
Clinical Oncology (2024) Vol. 36, Iss. 10, pp. e408-e419
Closed Access | Times Cited: 5
Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis
Lavinia Balan, Anca Maria Cîmpean, Prashant Sunil Nandarge, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1109-1109
Open Access | Times Cited: 4
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
Ke Wang, Chuangjie Zheng, Xinrong Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
Wenzhao Li, Wisam Najdawi, Omar Badla, et al.
Seminars in Ophthalmology (2025), pp. 1-11
Closed Access
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma
Siqi Ren, Yinping Zhang, Xingyue Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Reprogramming the tumor microenvironment by targeting cytidine deaminase in pancreatic ductal adenocarcinoma tumors: implications for the role of P2Y6 receptors
Abdel-Aziz S. Shatat
Purinergic Signalling (2025)
Open Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives
Zhiyao Chen, Yunbin Ma, Jianan Chen
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies
Suman Giri, Gopal Lamichhane, Jitendra Pandey, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2923-2923
Open Access
Optimization of Cancer Immunotherapy Through Synergistic Enhancement of Immunogenic Cell Death by Multifunctional Nanobioreactors Combined with Immune Checkpoint Inhibitors
Hui Zhang, Chunyu Qu, Ziqing Yang, et al.
ACS Applied Nano Materials (2025)
Closed Access
Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation
Paras Famta, Saurabh Shah, Ganesh Vambhurkar, et al.
Drug Delivery and Translational Research (2024) Vol. 15, Iss. 2, pp. 389-406
Closed Access | Times Cited: 4
Delineated 3-1-BenCarMethInYlPro-Phosphonic Acid’s Adroit Activity against Lung Cancer through Multitargeted Docking, MM\GBSA, QM-DFT and Multiscale Simulations
Mohammed Ageeli Hakami, Ali Hazazi, Fawaz Albloui, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 592-592
Open Access | Times Cited: 2
Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer
Abdulkarim S. Binshaya, Omar Saad Alkahtani, Fahad M. Aldakheel, et al.
Medical Oncology (2024) Vol. 41, Iss. 5
Closed Access | Times Cited: 2
Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
J Pawlonka, Barbara Buchalska, Kasper Buczma, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1406-1427
Open Access | Times Cited: 2
New advances in the treatment of intermediate and advanced hepatocellular carcinoma
Zhonghao Jiang, Fan Yang
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
B Cell Dynamics in HIV Pathogenesis: Insights and Implications
Emmanuel Ifeanyi Obeagu
Annals of Immunology & Immunotherapy (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential
Pankaj Garg, Sravani Ramisetty, Ayalur Raghu Subbalakshmi, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116498-116498
Closed Access | Times Cited: 1
Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
Haoyue Qin, Huan Yan, Xing Zhang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top